Oxcarbazepine Tablet, Extended Release
NDC Package 27241-237-01
Package Information
Oxcarbazepine tablets is oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy). This formulation utilizes a tablet, extended release delivery system. Marketed by Ajanta Pharma Usa Inc., this product is identified by NDC 27241-237 and is authorized under FDA application ANDA217659.
Identification & Billing
- RxCUI: 1365653 - OXcarbazepine 150 MG 24HR Extended Release Oral Tablet
- RxCUI: 1365653 - 24 HR oxcarbazepine 150 MG Extended Release Oral Tablet
- RxCUI: 1365653 - oxcarbazepine 150 MG 24 HR Extended Release Oral Tablet
- RxCUI: 1365842 - OXcarbazepine 300 MG 24HR Extended Release Oral Tablet
- RxCUI: 1365842 - 24 HR oxcarbazepine 300 MG Extended Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 27241 - Ajanta Pharma Usa Inc.
- 27241-237 - Oxcarbazepine
- 27241-237-01 - 100 TABLET, EXTENDED RELEASE in 1 BOTTLE
- 27241-237 - Oxcarbazepine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 27241-237-01 identifies a specific commercial package of 100 tablet, extended release in 1 bottle of Oxcarbazepine, a human prescription drug labeled by Ajanta Pharma Usa Inc.. This tablet, extended release is formulated for oral use and contains oxcarbazepine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ajanta Pharma Usa Inc. on February 22, 2024. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy).
How is this Ajanta Pharma Usa Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 27241023701. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.